A director at Bangkok Dusit Medical Services Public Company Limited sold 1,000,000 shares at 31.250THB and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's ...
The tone of BDMS’ analyst meeting in reviewing its 2Q24 results was positive. Despite being in the low season, BDMS still posted a decent yoy growth. Management implemented effective and promising strategies in order to improve BDMS’ performance. We are positive on the company’s prospect which is poised to see a more outstanding growth in the upcoming high season in 3Q24. Maintain BUY. Target price: Bt32.00.
KEY HIGHLIGHTS Strategy Uncertainties Arise as Court Removes PM from Office The court’s verdict raises concerns for the equities market and sector regarding policy continuity and economic stimulus, especially commerce. Results Central Plaza Hotel (CENTEL TB/SELL/Bt32.75/Target: Bt46.00) 2Q24: Weaker-than-expected results. CH Karnchang PCL (CK TB/BUY/Bt18.00/Target: Bt26.50) 2Q24: In line with expectations; expect volatility from polit...
GREATER CHINA Results Nexteer (1316 HK/SELL/HK$2.89/Target: HK$1.50) 1H24: Earnings miss estimates on revenue. Maintain SELL. Cut target price from HK$2.20 to HK$1.50. Tencent Holdings (700 HK/BUY/HK$373.80/Target: HK$490.00) 2Q24: Solid margin expansion; reaccelerated online games revenue growth. Update Foxconn Industrial Internet (601138 CH/BUY/Rmb21.38/Target: Rmb30.00) AI business continues to accelerate, GB200 scheduled to ship i...
We expect to see BDMS with a net profit of 3.2b in 2Q24 (+3.4% yoy, -22.2% qoq), dropping qoq due to seasonality. Without the norovirus outbreak like last year, BDMS resumes its normal operation in the usual low season in 2Q24. We should still see a yoy growth, driven by the increase in patient volume (especially the international patients). Maintain BUY. Target price: Bt32.00.
GREATER CHINA Strategy Small-Mid Cap Monthly Reiterate BUY on Plover Bay Technologies. Sector Automobile Weekly: Sales of top 12 EV brands up 38% wow last week, in line. Maintain MARKET WEIGHT. Top BUYs: Geely, CATL and Tuopu. Top SELL: XPeng. INDONESIA Update Sarana Menara Nusantara (TOWR IJ/BUY/Rp745/Target: Rp890) Number of towers to jump 10% on a...
BDMS has been gradually improving in profitability ever since the COVID-19 outbreak eased. We should see steady growth going forward as international patients have returned and the daily volume has recovered. There are also factors supporting the growth in patient volume and treatment prices. However, we foresee a qoq drop in 2Q24 due to seasonality. Maintain BUY. Target price: Bt32.00.
GREATER CHINA Strategy Alpha Picks: December Conviction Calls: We add a mix of turnaround stocks and beneficiaries of policy support to our BUY list − CSPC, HKEX, Lenovo, Longfor, Pinduoduo and Sunny Optical. INDONESIA Strategy Alpha Picks: Underperformance With A 3.7% Return: Our picks are GOTO, BMRI, JSMR, TLKM, BBNI, NCKL, CTRA, MYOR and AKRA. MALAYSIA Strategy Alpha Picks: Still Focusing On Domestic Winners: Our Alpha Picks trounced the FBMKLCI in Nov 23, mostly thanks to Hume’s run-up. De...
GREATER CHINA Strategy Alpha Picks: November Conviction Calls: We add a mix of defensives and turnaround stocks − COSCO Shipping, CR Mixc, Great Wall Motor, Innovent, Link REIT and NetEase − to our BUY list. INDONESIA Strategy Alpha Picks: Outperformance Despite Negative Returns: Our picks: TLKM, BBNI, SMGR, NCKL, CTRA, MYOR, AKRA and CMRY. MALAYSIA Strategy Alpha Picks: Focusing On Domestic Winners: Our Alpha Picks underperformed the FBMKLCI in Oct 23. Nov 23 picks: BUY BURSA, EKOVEST, GENM, ...
GREATER CHINA Strategy Alpha Picks: October Conviction Calls: We expect further downside pressure, so we add SELLs on Henlius and Xpeng to the list, on top of BUYs on Anta, Lenovo, PICC P&C and SHKP. INDONESIA Strategy Alpha Picks: Potential Bull Market in 4Q23: Our picks: BBNI, SMGR, NCKL, MAPI, CTRA, MYOR, AKRA and CMRY. MALAYSIA Strategy Alpha Picks: A Handful Of Events To Capitalise On: Our Alpha Picks modestly outperformed the FBMKLCI in Sep 23. Oct 23 picks: BUY BURSA, HAPL, HUME, MAHB a...
We expect BDMS’s 2Q23 earnings to soften qoq on account of seasonality, despite being offset by a large number of appointments made by international patients in May- Jun 23 as well as several medical epidemics in Thailand. We expect BDMS’ 3Q23 to be highly robust as 3Q is the high season and the number of patients from the Middle East continues to recover. Maintain BUY. Target price: Bt33.00.
We are mildly optimistic after a site visit to Bangkok Rayong Hospital (BRH) and Bangkok Rayong Cancer Hospital (BRC) since the launch of BRC will strengthen BDMS’ healthcare competency and enhance competitiveness, despite having a slight concern on possible losses during the early phase of operation. We still favour BDMS due to its diversification of patient base. Maintain BUY. Target price: Bt33.00.
GREATER CHINA Sector Commodities: Weekly: Steel prices rally on sentiment recovery; rainy season ahead. Update China Tourism Group Duty Free (601888 CH/BUY/Rmb117.71/Target: Rmb167.00): Margin remains a key concern; uncertain about supporting policy. INDONESIA Update Kalbe Farma (KLBF IJ/BUY/Rp2,040/Target: Rp2,400): Firing on all cylinders with M&A, selling price increase and raw material price decline. MALAYSIA Update GHL Systems (GHLS MK/BUY/RM0.825/Target: RM1.00): Hit record-high quarterl...
BDMS reported a positive earnings surprise, hitting a new all-time high mostly driven by the consecutive recovery in international patients and robust gross margin. Although we expect limited room for aggressive growth from the high base and softening 2Q23 results, BDMS has the lowest downside risk among peers due to its diversification of patient bases. Upgrade to BUY. Target price: Bt33.00.
KEY HIGHLIGHTS Results Bangkok Chain Hospital (BCH TB/SELL/Bt18.80/Target: Bt17.30) 1Q23: A shocking earnings surprise to the downside on slumped margins. Downgrade to SELL Bangkok Dusit Medical Services (BDMS TB/BUY/Bt29.75/Target: Bt33.00) 1Q23: Earnings hit a new record high on robust revenue and margins. Upgrade to BUY. Bangkok Expressway and Metro (BEM TB/HOLD/Bt9.05/Target: Bt9.80) 1Q23: Earnings beat on lower-than-expected expenditure. GFPT (GFPT TB/BUY/Bt11.20/Target: Bt13.20) 1Q2...
We expect BDMS to report a small yoy drop and qoq increase in 1Q23 earnings, with international patients as a dominant growth driver. However, we expect a small margin contraction due to an expected increase in utility and staff expenses. Despite the positive outlook for 2023 and BDMS’ resilience to external uncertainties, upside is capped by its current demanding valuation. Maintain HOLD. Target price: Bt32.00.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.